Why the study?
Do different subclasses of 1,4 dihydropyridine calcium antagonists have different effects on cardiac outcomes in patients with hypertension and CAD?
Population
Patients with hypertension and coronary artery disease (CAD)
Design
Review
Authors
Loading...
May prompt subclass-specific caution in CAD patients; leaves open need for head-to-head outcome trials.
Do different subclasses of 1,4 dihydropyridine calcium antagonists have different effects on cardiac outcomes in patients with hypertension and CAD?
This review highlights that while 1,4 dihydropyridine calcium antagonists are used for hypertension and CAD, some subclasses may have detrimental cardiac outcomes.
Frans H. H. Leenen (1999) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: